Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 12, 2025 02:30 ET | Source: Enterome

Enterome raises $19 million to fund clinical development of its OncoMimics™ immunotherapy to treat Follicular Lymphoma

Proceeds to fund Phase 1/2 trial of EO2463 OncoMimics™, as a monotherapy or in combination, to treat multiple forms of indolent non-Hodgkin lymphoma (iNHL)$9 million from new investor The Institute...
February 26, 2024 13:00 ET | Source: DelveInsight Business Research LLP

Follicular Lymphoma Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies - AbbVie, Genmab, Novartis, Allogene Therapeutics, Pfizer, Genentech, Incyte Corporation, Bristol-Myers Squibb

New York, USA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Follicular Lymphoma Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies - AbbVie, Genmab, Novartis, Allogene...
September 14, 2023 09:51 ET | Source: Emergen Research

Global Minimal Residual Disease (MRD) Market Size to Reach USD 4,138.5 Million in 2030 | Emergen Research

Vancouver, Sept. 14, 2023 (GLOBE NEWSWIRE) -- The global Minimal Residual Disease (MRD) market size was USD 1,095.3 Million in 2021 and is expected to register a revenue CAGR of 16.04% during the...
June 13, 2022 08:00 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy

94% overall response rate and 78% complete response rate in patients with FL, including complete response in a patient previously treated with CD19-targeted CAR T therapy 100% overall response rate...
May 12, 2022 10:38 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid Congress

Favorable safety profile, high overall response and complete response rates, and CAR T persistence observed in patients with relapsed or refractory follicular lymphoma Data to be presented by Fred...